Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M
Agios and Alnylam have agreed on an exclusive global licensing deal worth $147.5 million for Agios to take over the development and commercialization of a polycythemia vera preclinical siRNA candidate.
Agios is paying $17.5 million upfront, with Alnylam receiving up to $130 million for development and regulatory milestone payments, on top of sales milestones and tiered royalties, according to a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.